Guidelines for standard dosage and correct administration of Bestifan
Belzutifan is a HIF-2α inhibitor indicated for the treatment of tumors associated with advanced clear cell renal cell carcinoma (ccRCC) and von Hippel-Lindau (VHL) disease. As a targeted therapy drug, Bestivan effectively delays the growth and spread of tumors by inhibiting the HIF-2α protein in tumor cells and blocking tumor growth signals caused by insufficient oxygen.
The standard recommended dose of besetifan is120 mg once daily, continued until disease progression or unacceptable toxicity. The drug needs to be taken orally, and patients should take it at a fixed time every day, preferably with food to increase the bioavailability of the drug.

During the period of taking the medicine, patients should follow the doctor's instructions and receive regular physical examinations, especially monitoring of liver function, kidney function and blood pressure. The maximum course of treatment for the drug is usually for the patient to continue taking it until the condition worsens or drug resistance occurs, but the specific course of treatment needs to be adjusted according to the patient's actual condition.
Besetivan treatment may involve some side effects, including anemia, hypertension, abnormal liver function, and headache. Therefore, patients should promptly report any discomfort or abnormal reactions while taking it. Common side effects are often controllable, but patients still need to check blood indicators regularly to detect potential toxic reactions as early as possible. For common side effects such as anemia, your doctor may recommend auxiliary treatments, such as supplementing with erythropoietin or adjusting drug dosage.
It should be noted that the method of taking besetifan requires patients not to miss medication. If a dose is missed, the dose should be replenished as soon as possible, but if it is close to the time of the next dose, the missed dose should be skipped, and do not take a double dose on the same day to avoid adverse reactions caused by drug overdose.
Reference materials:https://www.welireg.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)